FTLP16: A Drug Target / Disease Biomarker (G100420158)
FTLP16: A Drug Target / Disease Biomarker
FTLP16 is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also has been shown to be involved in the development of other neurological disorders, such as ALS and multiple sclerosis.
FTLP16 is a transmembrane protein that is expressed in the brain and is primarily localized to the axons and dendrites of neurons. It is composed of four distinct domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a C-terminal tail. The extracellular domain is responsible for FTLP16's ability to interact with other proteins, the transmembrane domain is responsible for the protein's ability to traverse the membrane and the intracellular domain is responsible for the protein's ability to interact with intracellular signaling pathways. The C-terminal tail is responsible for the protein's ability to interact with other proteins and also plays a role in the regulation of the protein's stability.
FTLP16 is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and the build-up of waste material, which can lead to a range of symptoms, including memory loss, confusion, and difficulty with daily activities. Studies have shown that FTLP16 is involved in the development and progression of these diseases by regulating the function of neurons and the immune system.
FTLP16 has also been shown to be involved in the development of other neurological disorders, such as ALS and multiple sclerosis. ALS is a progressive neurodegenerative disease that is characterized by the progressive loss of motor neurons. Studies have shown that FTLP16 is involved in the development and progression of ALS by regulating the function of neurons and the immune system. Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system and is characterized by the progressive loss of muscle strength and stiffness. Studies have shown that FTLP16 is involved in the development and progression of multiple sclerosis by regulating the function of immune cells and the blood-brain barrier.
In addition to its involvement in the development and progression of neurodegenerative diseases, FTLP16 has also been shown to be involved in the regulation of other physiological processes in the body. For example, studies have shown that FTLP16 is involved in the regulation of blood flow to the brain and that it plays a role in the development of blood-brain barriers. These barriers are responsible for protecting the brain from the entry of harmful substances and are thought to be a potential target for the development of neurotoxic drugs.
Given its involvement in the development and progression of neurodegenerative diseases and its potential role in the regulation of other physiological processes, FTLP16 is a promising drug target for the development of new treatments for these diseases. Studies are currently being conducted to determine the exact mechanisms by which FTLP16 contributes to the development and progression of neurodegenerative diseases and to identify potential small molecules that can inhibit its function. If successful, these studies could lead to the development of new treatments for Alzheimer's disease, Parkinson's disease, ALS, and other neurological disorders.
Protein Name: Ferritin Light Chain Pseudogene 16
The "FTLP16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTLP16 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5
